PMID- 21303629
OWN - NLM
STAT- MEDLINE
DCOM- 20110607
LR  - 20221207
IS  - 1932-2968 (Electronic)
IS  - 1932-2968 (Linking)
VI  - 5
IP  - 1
DP  - 2011 Jan 1
TI  - No relevant relationship between glucose variability and oxidative stress in 
      well-regulated type 2 diabetes patients.
PG  - 86-92
AB  - BACKGROUND: A strong relationship between glycemic variability and oxidative 
      stress in poorly regulated type 2 diabetes (T2DM) on oral medication has been 
      reported. However, this relationship was not seen in type 1 diabetes. The purpose 
      of this study is to reexamine the relation between glycemic variability and 
      oxidative stress in a cohort of T2DM patients on oral medication. METHODS: 
      Twenty-four patients with T2DM on oral glucose lowering treatment underwent 48 
      hours of continuous glucose monitoring (CGMS(R) System GoldTM, Medtronic MiniMed) 
      and simultaneous collection of two consecutive 24-hour urine samples for 
      determination of 15(S)-8-iso-prostaglandin F2alpha (PGF2alpha) using high-performance 
      liquid chromatography tandem mass spectrometry. Standard deviation (SD) and mean 
      amplitude of glycemic excursions (MAGE) were calculated as markers of glycemic 
      variability. RESULTS: Included in the study were 66.7% males with a mean age 
      (range) of 59 (36-76) years and a mean (SD) HbA1c of 6.9% (0.7). Median 
      [interquartile range (IQR)] urinary 15(S)-8-iso-PGF2alpha excretion was 176.1 
      (113.6-235.8) pg/mg creatinine. Median (IQR) SD was 31 (23-40) mg/dl and MAGE 85 
      (56-106) mg/dl. Spearman correlation did not show a significant relation for SD 
      (rho = 0.15, p = .49) or MAGE (rho = 0.23, p = .29) with 15(S)-8-iso-PGF2alpha excretion. 
      Multivariate regression analysis adjusted for age, sex, HbA1c, and exercise did 
      not alter this observation. CONCLUSIONS: We did not find a relevant relationship 
      between glucose variability and 15(S)-8-iso-PGF2alpha excretions in T2DM patients 
      well-regulated with oral medication that would support an interaction between 
      hyperglycemia and glucose variability with respect to the formation of reactive 
      oxygen species.
CI  - (c) 2010 Diabetes Technology Society.
FAU - Siegelaar, Sarah E
AU  - Siegelaar SE
AD  - Department of Internal Medicine, Academic Medical Center, Amsterdam, The 
      Netherlands. s.e.siegelaar@amc.uva.nl
FAU - Barwari, Temo
AU  - Barwari T
FAU - Kulik, Wim
AU  - Kulik W
FAU - Hoekstra, Joost B
AU  - Hoekstra JB
FAU - DeVries, J Hans
AU  - DeVries JH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20110101
PL  - United States
TA  - J Diabetes Sci Technol
JT  - Journal of diabetes science and technology
JID - 101306166
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 27415-26-5 (8-epi-prostaglandin F2alpha)
RN  - B7IN85G1HY (Dinoprost)
SB  - IM
CIN - J Diabetes Sci Technol. 2012 Jan;6(1):218-9; author reply 220-1. PMID: 22401342
MH  - Adult
MH  - Aged
MH  - Blood Glucose/analysis/*metabolism
MH  - Blood Glucose Self-Monitoring/instrumentation/methods/standards/statistics & 
      numerical data
MH  - Diabetes Mellitus, Type 2/*blood/*metabolism/therapy/urine
MH  - Dinoprost/analogs & derivatives/urine
MH  - Fasting/blood/metabolism/urine
MH  - Female
MH  - Glycated Hemoglobin/analysis/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Observer Variation
MH  - Oxidative Stress/*physiology
MH  - Postprandial Period/physiology
MH  - Treatment Outcome
PMC - PMC3045241
EDAT- 2011/02/10 06:00
MHDA- 2011/06/08 06:00
PMCR- 2012/01/01
CRDT- 2011/02/10 06:00
PHST- 2011/02/10 06:00 [entrez]
PHST- 2011/02/10 06:00 [pubmed]
PHST- 2011/06/08 06:00 [medline]
PHST- 2012/01/01 00:00 [pmc-release]
AID - dst.5.1.086 [pii]
AID - 10.1177/193229681100500112 [doi]
PST - epublish
SO  - J Diabetes Sci Technol. 2011 Jan 1;5(1):86-92. doi: 10.1177/193229681100500112.